Results Presented at CODHy Conference
HAYWARD, Calif., Nov. 12 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982. A summary of the results was presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) on November 1, 2008.
MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that MBX-2982 is a potent selective orally active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. This dual action is unique and may offer improved glucose homeostasis over existing diabetes therapies, with potential for weight loss and improved islet health.
The Phase 1a study was a randomized, placebo-controlled, double-blind, ascending-dose clinical trial in 60 healthy male and female volunteers examining doses of MBX-2982 in the 10 - 1000 mg range. All doses of the drug were well tolerated and no dose-related adverse events were observed. MBX-2982 was rapidly absorbed, demonstrated excellent exposure and exhibited a half- life consistent with once-daily dosing. As observed in preclinical studies in animals, MBX-2982 showed dose-dependent reductions in glucose and increases in GLP-1 following a mixed meal. These results provide initial clinical validation of the unique mechanism of action of MBX-2982.
"The results of this Phase 1a clinical trial are very encouraging and
support the continued development of MBX-2982 as an important new thera
Copyright©2008 PR Newswire.
All rights reserved